Foghorn Therapeutics Stock Forecast
NASDAQ: FHTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 2.01 +1.00%
FHTX analyst consensus
Consensus (10 analysts)
buy
Avg. price target
$6.00+201.51%
- Strong buy 0
- Buy 6
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Foghorn Therapeutics (2026-10-08), 6 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $6.00, with a high estimate of $14.00 and a low estimate of $2.00. The average target implies upside of 201.5% from the current price of $1.99.
The spread between the highest and lowest targets is 600.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for FHTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 6 | 60% |
| Hold | 4 | 40% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.00 | +0.50% |
| Average target | $6.00 | +201.51% |
| High target | $14.00 | +603.52% |